Ivosenib 250 mg (Ivosidenib) Tablets

IVOSENIB (Ivosidenib) 250 mg is a targeted anticancer medicine used in adults with IDH1 mutation-positive Acute Myeloid Leukemia (AML) confirmed through an approved diagnostic test. By specifically targeting the abnormal IDH1 enzyme, it helps reduce the growth and survival of leukemia cells while supporting the production of healthy blood cells.

Therapeutic Effects

• Helps treat IDH1 mutation-positive Acute Myeloid Leukemia (AML).
• Slows the growth and spread of abnormal leukemia cells.
• Promotes the maturation of immature blood cells into healthy blood cells.
• Supports disease management in eligible newly diagnosed or relapsed/refractory AML patients.
• Used under the supervision of an experienced oncology specialist as part of a personalized treatment plan.

Active Ingredient

• Ivosidenib 250 mg

Composition
Each film-coated tablet contains:

• Ivosidenib USP 250 mg

Pharmaceutical Form

• Film-Coated Tablet
• Oral Administration

IVOSENIB belongs to the IDH1 inhibitor class of targeted anticancer medicines designed to selectively inhibit mutant isocitrate dehydrogenase-1 (IDH1) enzymes.

IVOSENIB should be taken only under the supervision of a qualified healthcare professional experienced in cancer treatment.

Recommended Adult Dose

• 500 mg orally once daily (typically two 250 mg tablets), or as prescribed by the treating physician.

Administration Instructions

• Swallow tablets whole with water.
• Take at the same time each day.
• May be taken with or without food.
• Avoid high-fat meals around the time of dosing if advised by your healthcare provider.
• Do not crush, split, or chew the tablets.

Missed Dose

• If a dose is missed and less than 12 hours remain before the next scheduled dose, skip the missed dose and continue the regular schedule.
• Do not take two doses at the same time to make up for a missed dose.

Important Advice

• Continue treatment exactly as prescribed.
• Regular blood tests, ECG monitoring, and liver function assessments may be required during therapy.
• Do not change or stop the medicine without consulting your oncologist.

Medical Disclaimer: Dosage may vary depending on the patient's condition, response to treatment, and current clinical guidelines. Always follow the prescribing physician's instructions.